

# Nuno C Taveira

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7265152/publications.pdf>

Version: 2024-02-01

115  
papers

48,306  
citations

126901

33  
h-index

26610

107  
g-index

124  
all docs

124  
docs citations

124  
times ranked

60924  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evolution of the prevalence and incidence of oral disorders in Portugal, 1990â€“2016: findings from the Global Burden of Disease 2016 Study. <i>Annals of Medicine</i> , 2024, 51, 67-67.	3.8	0
2	Antibody neutralization and its determinants in HIV-1 infected patients from Portugal: implications for vaccine design and efficacy. <i>Annals of Medicine</i> , 2024, 51, 89-89.	3.8	0
3	Structural elucidation and molecular dynamics study targeting the viral surface glycoproteins against HIV-2 infection. <i>Annals of Medicine</i> , 2024, 51, 151-151.	3.8	0
4	Broad Spectrum Functional Activity of Structurally Related Monoanionic Au(III) Bis(Dithiolene) Complexes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7146.	4.1	5
5	Anti-HIV-1 Activity of pepRF1, a Proteolysis-Resistant CXCR4 Antagonist Derived from Dengue Virus Capsid Protein. <i>ACS Infectious Diseases</i> , 2021, 7, 6-22.	3.8	3
6	Mapping routine measles vaccination in low- and middle-income countries. <i>Nature</i> , 2021, 589, 415-419.	27.8	71
7	Spiro-Î²-lactam BSS-730A Displays Potent Activity against HIV and Plasmodium. <i>ACS Infectious Diseases</i> , 2021, 7, 421-434.	3.8	11
8	Diagnosis of SARS-Cov-2 Infection by RT-PCR Using Specimens Other Than Naso- and Oropharyngeal Swabs: A Systematic Review and Meta-Analysis. <i>Diagnostics</i> , 2021, 11, 363.	2.6	44
9	Computational Modulation of the V3 Region of Glycoprotein gp125 of HIV-2. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1948.	4.1	3
10	Antibody response against selected epitopes in the HIV-1 envelope gp41 ectodomain contributes to reduce viral burden in HIV-1 infected patients. <i>Scientific Reports</i> , 2021, 11, 8993.	3.3	5
11	Synthesis and structure-activity relationships of new chiral spiro-Î²-lactams highly active against HIV-1 and Plasmodium. <i>European Journal of Medicinal Chemistry</i> , 2021, 219, 113439.	5.5	19
12	Probiotics in Oral Health and Disease: A Systematic Review. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 8070.	2.5	15
13	Inhibition of HIV replication through siRNA carried by CXCR4-targeted chimeric nanobody. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 2859-2870.	5.4	14
14	Genotypic resistance profiles of HIV-2-infected patients from Cape Verde failing first-line antiretroviral therapy. <i>Aids</i> , 2020, 34, 483-486.	2.2	2
15	Global burden of 369 diseases and injuries in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1204-1222.	13.7	7,664
16	Global burden of 87 risk factors in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1223-1249.	13.7	3,928
17	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950â€“2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1160-1203.	13.7	890
18	Five insights from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1135-1159.	13.7	335

#	ARTICLE	IF	CITATIONS
19	Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain. Scientific Reports, 2020, 10, 13024.	3.3	1
20	Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000â€“17: analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 1779-1801.	13.7	72
21	Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance. Nature Microbiology, 2020, 5, 443-454.	13.3	114
22	Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2. Journal of Infectious Diseases, 2020, 221, 1962-1972.	4.0	14
23	A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies. Vaccines, 2020, 8, 171.	4.4	6
24	Pyromellitic dianhydride crosslinked soluble cyclodextrin polymers: Synthesis, lopinavir release from sub-micron sized particles and anti-HIV-1 activity. International Journal of Pharmaceutics, 2020, 583, 119356.	5.2	17
25	Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. Nature Medicine, 2020, 26, 750-759.	30.7	47
26	Predicting the evolution and control of the COVID-19 pandemic in Portugal. F1000Research, 2020, 9, 283.	1.6	7
27	Predicting the evolution and control of the COVID-19 pandemic in Portugal. F1000Research, 2020, 9, 283.	1.6	13
28	Spiro-Lactams as Novel Antimicrobial Agents. Current Topics in Medicinal Chemistry, 2020, 20, 140-152.	2.1	16
29	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. Nature, 2019, 574, 353-358.	27.8	161
30	Global, regional, and national incidence, prevalence, and mortality of HIV, 1980â€“2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV,the, 2019, 6, e831-e859.	4.7	341
31	HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study. Scientific Reports, 2019, 9, 5606.	3.3	22
32	PO 8597â€¦NEUTRALISING AND NON-NEUTRALISING ANTIBODIES RESPONSE IN HIV-1-INFECTED INDIVIDUALS FROM MOZAMBIQUE. BMJ Global Health, 2019, 4, A61.2-A61.	4.7	0
33	InÂvitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2. Antiviral Research, 2019, 161, 85-89.	4.1	3
34	Clonal expansion across the seas as seen through CPLP-TB database: A joint effort in cataloguing Mycobacterium tuberculosis genetic diversity in Portuguese-speaking countries. Infection, Genetics and Evolution, 2019, 72, 44-58.	2.3	18
35	Mitochondrial DNA in human identification: a review. PeerJ, 2019, 7, e7314.	2.0	67
36	Trends in HIV/AIDS morbidity and mortality in Eastern Mediterranean countries, 1990â€“2015: findings from the Global Burden of Disease 2015 study. International Journal of Public Health, 2018, 63, 123-136.	2.3	13

#	ARTICLE	IF	CITATIONS
37	Global, regional, and national age-sex-specific mortality and life expectancy, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1684-1735.	13.7	716
38	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1736-1788.	13.7	4,989
39	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1923-1994.	13.7	3,269
40	Population and fertility by age and sex for 195 countries and territories, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1995-2051.	13.7	294
41	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1789-1858.	13.7	8,569
42	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 2091-2138.	13.7	335
43	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1859-1922.	13.7	2,123
44	Noncovalent PEG Coating of Nanoparticle Drug Carriers Improves the Local Pharmacokinetics of Rectal Anti-HIV Microbicides. ACS Applied Materials & Interfaces, 2018, 10, 34942-34953.	8.0	32
45	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, The, 2018, 391, 2236-2271.	13.7	638
46	Evaluation of the fusion inhibitor P3 peptide as a potential microbicide to prevent HIV transmission in women. PLoS ONE, 2018, 13, e0195744.	2.5	6
47	Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. Scientific Reports, 2018, 8, 12266.	3.3	16
48	Accidental Father-to-Son HIV-1 Transmission During the Seroconversion Period. AIDS Research and Human Retroviruses, 2018, 34, 857-862.	1.1	6
49	HIV-2 Envelope: Structure, Diversity, and Evolution. , 2018, , 945-949.		0
50	Genetic diversity, transmission dynamics and drug resistance of Mycobacterium tuberculosis in Angola. Scientific Reports, 2017, 7, 42814.	3.3	17
51	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990â€“2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	13.7	480
52	Assessment of the CaviDi ExaVir Load Assay for Monitoring Plasma Viral Load in HIV-2-Infected Patients. Journal of Clinical Microbiology, 2017, 55, 2367-2379.	3.9	6
53	Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015â€“16: a modelling study. Lancet Infectious Diseases, The, 2017, 17, 330-338.	9.1	185
54	Potency of HIV-2-specific antibodies increase in direct association with loss of memory B cells. Aids, 2017, 31, 2431-2433.	2.2	6

#	ARTICLE	IF	CITATIONS
55	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1084-1150.	13.7	573
56	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1260-1344.	13.7	1,589
57	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1151-1210.	13.7	3,565
58	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1211-1259.	13.7	5,578
59	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1423-1459.	13.7	284
60	Donor-Recipient Identification in Para- and Poly-phyletic Trees Under Alternative HIV-1 Transmission Hypotheses Using Approximate Bayesian Computation. Genetics, 2017, 207, 1089-1101.	2.9	12
61	A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. Journal of Virology, 2017, 91, .	3.4	35
62	Computational Approach to Structural and Conformational Characterization of Viral Surface Glycoproteins of HIV-2. Proceedings (mdpi), 2017, 1, 228.	0.2	0
63	Early infant diagnosis of HIV-1 infection in Luanda, Angola, using a new DNA PCR assay and dried blood spots. PLoS ONE, 2017, 12, e0181352.	2.5	8
64	Genetic diversity, transmission dynamics, and drug resistance of Mycobacterium tuberculosis in Luanda, Angola. International Journal of Mycobacteriology, 2016, 5, S38-S39.	0.6	1
65	A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support. Retrovirology, 2016, 13, 85.	2.0	13
66	Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors. Aids, 2016, 30, 1691-1701.	2.2	12
67	Rare HIV-1 Subtype J Genomes and a New H/U/CRF02_AG Recombinant Genome Suggests an Ancient Origin of HIV-1 in Angola. AIDS Research and Human Retroviruses, 2016, 32, 822-828.	1.1	11
68	On the contribution of Angola to the initial spread of HIV-1. Infection, Genetics and Evolution, 2016, 46, 219-222.	2.3	11
69	Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates. Journal of Virology, 2016, 90, 11062-11074.	3.4	12
70	P-B3â€fEvaluation of an in-house molecular HIV-1 Test to assess Mother-to-Child HIV-1 transmission in angola (the APEHC cohort). Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 73.	2.1	0
71	Development of water-soluble polyanionic carbosilane dendrimers as novel and highly potent topical anti-HIV-2 microbicides. Nanoscale, 2015, 7, 14669-14683.	5.6	33
72	Determinants of Highly Active Antiretroviral Therapy Duration in HIV-1-Infected Children and Adolescents in Madrid, Spain, from 1996 to 2012. PLoS ONE, 2014, 9, e96307.	2.5	7

#	ARTICLE	IF	CITATIONS
73	HIV-1 Diversity, Transmission Dynamics and Primary Drug Resistance in Angola. PLoS ONE, 2014, 9, e113626.	2.5	17
74	Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response. Retrovirology, 2013, 10, 110.	2.0	11
75	An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity. Aids, 2013, 27, 1081-1090.	2.2	25
76	HIV-2 Envelope: Structure, Diversity, and Evolution. , 2013, , 1-6.		1
77	Predictors of Attrition and Immunological Failure in HIV-1 Patients on Highly Active Antiretroviral Therapy from Different Healthcare Settings in Mozambique. PLoS ONE, 2013, 8, e82718.	2.5	21
78	HIV-2 susceptibility to entry inhibitors. AIDS Reviews, 2013, 15, 49-61.	1.0	3
79	Memory B-cell depletion is a feature of HIV-2 infection even in the absence of detectable viremia. Aids, 2012, 26, 1607-1617.	2.2	13
80	Baseline susceptibility of primary HIV-2 to entry inhibitors. Antiviral Therapy, 2012, 17, 565-570.	1.0	44
81	Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism. Aids, 2012, 26, 2275-2284.	2.2	23
82	Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A. Journal of General Virology, 2012, 93, 889-899.	2.9	56
83	Genetic Diversity and Drug Resistance Profiles in HIV Type 1- and HIV Type 2-Infected Patients from Cape Verde Islands. AIDS Research and Human Retroviruses, 2012, 28, 510-522.	1.1	6
84	HIV-1 Diversity and Its Implications in Diagnosis, Transmission, Disease Progression, and Antiretroviral Therapy. , 2012, , .		4
85	Evaluation of the diagnostic performance of the rapid test VIKIA HIV1/2 in a highly complex HIV-1 epidemic. Diagnostic Microbiology and Infectious Disease, 2011, 71, 90-92.	1.8	7
86	Evolutionary and Structural Features of the C2, V3 and C3 Envelope Regions Underlying the Differences in HIV-1 and HIV-2 Biology and Infection. PLoS ONE, 2011, 6, e14548.	2.5	27
87	Origin and Epidemiological History of HIV-1 CRF14_BG. PLoS ONE, 2011, 6, e24130.	2.5	28
88	Potent and Broadly Reactive HIV-2 Neutralizing Antibodies Elicited by a Vaccinia Virus Vector Prime-C2V3C3 Polypeptide Boost Immunization Strategy. Journal of Virology, 2010, 84, 12429-12436.	3.4	22
89	HIV-2 Genetic Evolution in Patients with Advanced Disease Is Faster than That in Matched HIV-1 Patients. Journal of Virology, 2010, 84, 7412-7415.	3.4	26
90	Outbreak of Acute Respiratory Infection among Infants in Lisbon, Portugal, Caused by Human Adenovirus Serotype 3 and a New 7/3 Recombinant Strain. Journal of Clinical Microbiology, 2010, 48, 1391-1396.	3.9	46

#	ARTICLE	IF	CITATIONS
91	Rapid clinical progression to AIDS and death in a persistently seronegative HIV-1 infected heterosexual young man. <i>Aids</i> , 2009, 23, 2359-2362.	2.2	12
92	Antiretroviral Drug Resistance Surveillance among Treatment-Naïve Human Immunodeficiency Virus Type 1-Infected Individuals in Angola: Evidence for Low Level of Transmitted Drug Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3156-3158.	3.2	20
93	Highly divergent subtypes and new recombinant forms prevail in the HIV/AIDS epidemic in Angola: New insights into the origins of the AIDS pandemic. <i>Infection, Genetics and Evolution</i> , 2009, 9, 672-682.	2.3	44
94	HIV-1 Genetic Diversity and Transmitted Drug Resistance in Health Care Settings in Maputo, Mozambique. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 323-331.	2.1	25
95	The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients. <i>Retrovirology</i> , 2008, 5, 78.	2.0	23
96	Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression. <i>Aids</i> , 2008, 22, 2257-2265.	2.2	16
97	Synonymous Substitution Rates Predict HIV Disease Progression as a Result of Underlying Replication Dynamics. <i>PLoS Computational Biology</i> , 2007, 3, e29.	3.2	152
98	Use of a New Dual-Antigen Enzyme-Linked Immunosorbent Assay To Detect and Characterize the Human Antibody Response to the Human Immunodeficiency Virus Type 2 Envelope gp125 and gp36 Glycoproteins. <i>Journal of Clinical Microbiology</i> , 2006, 44, 607-611.	3.9	17
99	Evidence for negative selective pressure in HIV-2 evolution in vivo. <i>Infection, Genetics and Evolution</i> , 2005, 5, 239-246.	2.3	25
100	High Genetic Diversity of Human Immunodeficiency Virus Type 1 in Angola. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 306-310.	1.1	22
101	Synonymous Substitution Rates Predict HIV Disease Progression as a Result of Underlying Replication Dynamics. <i>PLoS Computational Biology</i> , 2005, preprint, e29.	3.2	1
102	Phylogenetic Demonstration of Two Cases of Perinatal Human Immunodeficiency Virus Type 2 Infection Diagnosed in Adulthood. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 1373-1376.	1.1	9
103	Seronegative infection and AIDS caused by an A2 subsubtype HIV-1. <i>Aids</i> , 2004, 18, 1071-1074.	2.2	13
104	Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection. <i>Virology</i> , 2003, 308, 225-232.	2.4	23
105	Construction and characterization of CD4-independent infectious recombinant HIV-2 molecular clones. <i>Virus Research</i> , 2003, 97, 159-163.	2.2	9
106	Evaluation of the Clinical Sensitivities of Three Viral Load Assays with Plasma Samples from a Pediatric Population Predominantly Infected with Human Immunodeficiency Virus Type 1 Subtype G and BG Recombinant Forms. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3361-3367.	3.9	37
107	Production and Characterization of a Mouse Monoclonal Antibody against the Gag p26 Protein of Human Immunodeficiency Virus Type 2: Identification of a New Antigenic Epitope. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1279-1283.	1.1	1
108	Perinatally acquired HIV-2 infection diagnosed at 15 and 24 years of age. <i>Aids</i> , 2001, 15, 2460-2461.	2.2	9



#	ARTICLE	IF	CITATIONS
109	Quantitation of Human Immunodeficiency Virus Type 2 DNA in Peripheral Blood Mononuclear Cells by Using a Quantitative-Competitive PCR Assay. Journal of Clinical Microbiology, 1999, 37, 453-456.	3.9	28
110	Virological and Molecular Demonstration of Human Immunodeficiency Virus Type 2 Vertical Transmission. Journal of Virology, 1998, 72, 3418-3422.	3.4	22
111	Vertical transmission of HIV-2. Lancet, The, 1997, 349, 177-178.	13.7	13
112	Amplification of full-length HIV-2 envelope genes. Molecular and Cellular Probes, 1996, 10, 91-98.	2.1	1
113	Molecular Characterization of the env Gene from a Non-Syncytium-Inducing HIV-2 Isolate (HIV-2ALI). AIDS Research and Human Retroviruses, 1994, 10, 223-224.	1.1	12
114	Detection of HIV-1 DNA by polymerase chain reaction incorporation of digoxigenin-11-dUTP and hybridization to immobilized probes. Molecular and Cellular Probes, 1994, 8, 235-240.	2.1	2
115	Detection of HIV1 proviral DNA by PCR and hybridization with digoxigenin labelled probes. Molecular and Cellular Probes, 1992, 6, 265-270.	2.1	6